← Back to Clinical Trials
Recruiting NCT07249749

NCT07249749 Factor Associated With Mortality in the ICU

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07249749
Status Recruiting
Phase
Sponsor Hospital Departamental de Villavicencio
Condition Critically Ill
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2026-01-10
Primary Completion 2028-12-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL
Interventions
Exposure factors

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2026-01-10 with a primary completion date of 2028-12-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

ICU mortality indicates the severity of disease, healthcare quality, and the efficacy of interventions. The severity scores are tools to predict the risk of mortality in the ICU, and the APACHE II score is frequently used for this purpose. However, studies validating the score in Colombia are limited. There is uncertainty about the precision and discrimination capacity of the APACHE II score in a population that varies from the original, with varying diseases, and in a different timeline. The investigators determined to evaluate: 1. Evaluate the rate of mortality in the ICU by type of disease and type of admission. 2. The factors associated with mortality. 3. Validate the performance of the APACHE II score as a predictor of mortality.

Eligibility Criteria

Inclusion Criteria: * All adult patients older than 18 admitted to the intensive care unit during the study period. Exclusion Criteria: * Patients admitted for intermediate care (low therapeutic intervention with a TISS \[Therapeutic Intervention Scoring System\] - 28 score below 20 points). Patients derived to other institutions.

Contact & Investigator

Central Contact

Norton Perez Gutierrez, MD

✉ norton.perez@hotmail.com

📞 3112517471

Principal Investigator

Norton Perez Gutierrez, MD

PRINCIPAL INVESTIGATOR

Hospital Departamental de Villavicencio

Frequently Asked Questions

Who can join the NCT07249749 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Critically Ill. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07249749 currently recruiting?

Yes, NCT07249749 is actively recruiting participants. Contact the research team at norton.perez@hotmail.com for enrollment information.

Where is the NCT07249749 trial being conducted?

This trial is being conducted at Villavicencio, Colombia.

Who is sponsoring the NCT07249749 clinical trial?

NCT07249749 is sponsored by Hospital Departamental de Villavicencio. The principal investigator is Norton Perez Gutierrez, MD at Hospital Departamental de Villavicencio. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology